{"filings":[{"id":816076,"accession_number":"0001213900-26-064460","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2026-06-03T12:27:22+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rocket One appoints Major General Malcolm Frost (Ret.) to Advisory Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Major General Frost brings 31 years of U.S. Army leadership; served as Chief of Public Affairs and Deputy Director for Operations at NMCC.","He will guide technical development of AI computing and memory hardware for space and defense environments.","Rocket One (Nasdaq: RKTO) develops advanced computing technologies for AI acceleration, radiation-tolerant computing, and space systems.","Appointment effective June 3, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":816077,"accession_number":"0001213900-26-064457","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2026-06-03T12:26:22+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rocket One raises ATM offering capacity by $6.83M; $9.28M already sold under agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rocket One increased ATM offering cap by $6.83M; H.C. Wainwright acts as agent.","Approximately $9.28M of stock sold under ATM since Nov 2024 agreement.","Prospectus supplement and legal opinion filed with SEC on June 3.","Shares sold at market prices; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":806249,"accession_number":"0001213900-26-064177","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2026-06-02T20:15:23+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rocket One appoints Dr. Supriyo Bandyopadhyay as Lead Technical Advisor for AI nanomagnetic chip tech","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Bandyopadhyay is a Commonwealth Professor at Virginia Commonwealth University and nanomagnetics/spintronics authority.","He will guide technical development of the company's radiation-tolerant, ultra-low-power AI chip platform for space and defense.","Appointment deepens technical link between Rocket One's platform and foundational research from which it is derived.","CEO Robb Knie says move signals transition from launch story to compute story for orbital economy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":705519,"accession_number":"0001213900-26-061789","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2026-05-28T12:25:17+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rocket One accepted into AMD AI Developer Program for nanomagnetic AI accelerator simulation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Accepted into AMD AI Developer Program, gaining access to AI cloud resources, technical training, and developer tools.","Will use program resources to support early-stage simulation of nanomagnetic/spintronic semiconductor AI accelerator architecture.","Company holds exclusive rights to patent applications for nanomagnetic computing technologies targeting AI, defense, and space applications.","Increased ATM offering by up to $2,661,176 (sold ~$6.6M to date); filed prospectus supplement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":677996,"accession_number":"0001213900-26-061252","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2026-05-27T12:33:47+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics renames to Rocket One Inc.; ticker changes to RKTO, pivots to space AI chip tech","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change effective May 26, 2026; new ticker RKTO starts trading on Nasdaq May 28, 2026.","Company holds exclusive rights to nanomagnetic AI chip technology for space and defense applications.","Chip retains data without power, uses ultra-low energy, and is radiation-tolerant for orbital environments.","Legacy biotech programs will continue under a wholly owned subsidiary.","Targets satellite, defense, and AI systems power-constrained orbital economy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":582596,"accession_number":"0001213900-26-060075","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2026-05-21T20:25:43+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics to restructure as Rocket One, entering AI chip licensing deal with VCU","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive licenses from VCU for nanomagnetic matrix multiplier (AI acceleration) and spintronic memory for defense/space.","Royalties: mid-single-digit % on net sales (patents), low-single-digit % for technical info, low-double-digit % on sublicensing.","Minimum annual payments low to mid five figures; one agreement had low-five-figure upfront fee.","Company intends to change name to Rocket One Inc.; restructuring approved by board to pursue AI semiconductor infrastructure.","Biotechnology assets will be placed in a separate wholly owned subsidiary to preserve value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94907,"accession_number":"0001213900-26-052803","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Hoth Therapeutics forms Rocket One subsidiary for space industry assets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Formed wholly-owned subsidiary Rocket One Inc. to enter space industry.","Rocket One to acquire, own and operate nano rocket systems for nanosatellite deployment.","Articles of Incorporation filed with Nevada Secretary of State on April 22, 2026.","No financial terms or timeline disclosed for space venture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94906,"accession_number":"0001213900-26-051728","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Hoth Therapeutics receives Nasdaq deficiency notice for minimum bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Hoth on April 30, 2026 that bid price closed below $1.00 for 30 consecutive business days (Mar 18 – Apr 29).","Company has 180 calendar days, until October 27, 2026, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured by Oct 27, additional 180 days may be granted if company meets other listing requirements.","Company may consider options including a reverse stock split to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94905,"accession_number":"0001213900-26-044741","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics resumes ATM equity offering under existing H.C. Wainwright agreement","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["On April 16, 2026, Hoth filed a new prospectus supplement to resume sales of common stock under its ATM agreement with H.C. Wainwright.","The ATM offering was previously suspended on April 1, 2026, but the Sales Agreement remained in effect.","The new prospectus supplement relates to the company's existing effective S-3 registration statement (File No. 333-291566).","No specific terms (size, price, or expected proceeds) were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94904,"accession_number":"0001213900-26-039363","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics closes $2.0M registered direct offering of 2.86M shares at $0.70 plus warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$2.0M from sale of 2,857,144 shares at $0.70 each; used for working capital.","Warrants issued: 2,857,144 shares at $0.85, exercisable 6 months from issuance, 5.5-year term.","Placement agent: H.C. Wainwright & Co. — 7% cash fee, 5% warrant coverage at $0.875 per share.","Company suspended its existing ATM equity program pending new prospectus supplement.","Offering closed April 2, 2026 as announced in a separate press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107608,"accession_number":"0001213900-26-004899","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics Files Presentation Materials for Weight Loss Drug and Pipeline Meetings with US Officials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prepared presentation for US government officials on weight loss drug HT-VA and broader therapeutics pipeline","HT-001 for skin toxicity from cancer therapy: Phase 2a data and full PK dataset expected Q1 2026","HT-KIT targeting mastocytosis and KIT-driven cancers: IND submission targeted for Q4 2026","HT-ALZ Alzheimer's program: preclinical data showing improved memory and reduced neuroinflammation","HT-VA obesity program licensed from VA; preclinical studies under CRADA initiated Q3 2025"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123978,"accession_number":"0001213900-25-099969","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics updates corporate presentation with clinical milestones and cash position","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HT-001 Phase 2a open-label cohort showed promising results; case study published Sept 2024.","HT-KIT IND-enabling tox studies initiated Q1 2024; target IND submission Q4 2026.","HT-ALZ patent awarded Q3 2024; preclinical studies at Washington University completed.","HT-VA license from Veteran's Affairs obtained Q1 2025; CRADA executed Q2 2025.","15.4M shares outstanding as of Oct 14, 2025; cash sufficient for clinical and preclinical programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140643,"accession_number":"0001213900-25-087054","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Hoth Therapeutics expands crypto treasury to include Ethereum and Solana","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved up to $1M in Bitcoin, Ethereum, and/or Solana as treasury reserve asset.","Aggregate purchases limited to 20% of cash on hand at time of purchase.","Supplemented risk factors citing volatility, no dividends, and counterparty risks.","Strategy is part of previously announced treasury reserve plan now expanded to additional cryptos."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140642,"accession_number":"0001213900-25-079915","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics enters new CEO employment agreement with $550k salary and 800k share grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Robb Knie's new employment agreement includes $550,000 annual base salary and up to $550,000 annual bonus.","800,000 shares of common stock granted to Knie, vesting fully on grant date August 27, 2025.","Agreement provides for transaction bonus tied to equity value if company engages in license, joint venture, or change of control.","Company filed PCT patent application for HT-001, a topical treatment for side effects of cancer drugs, claiming priority to two U.S. provisionals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140641,"accession_number":"0001213900-25-072068","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Hoth Therapeutics shareholders approve director re-election and plan amendment at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees (Knie, Sarnoff, Linsley, Pavell, Camarra) re-elected with strong support.","Ratification of Withum as auditor for FY2025 approved: 4,559,052 for, 247,728 against.","Amendment to 2022 Plan to increase share reserve from 1,091,317 to 3,091,317 shares approved.","Advisory vote on 2024 executive compensation approved: 1,098,368 for, 265,965 against.","Shareholders selected one-year frequency for future advisory votes on executive pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158364,"accession_number":"0001213900-25-057233","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Hoth Therapeutics reports 100% efficacy in Phase 2a of HT-001 for EGFRI skin toxicities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a CLEER-001 study: 100% of patients achieved primary endpoint; 66% reported reduced pain/itching.","All patients maintained EGFR inhibitor dosage while on HT-001, preserving cancer treatment.","Preclinical data showed 56% reduction in hair loss and 58% reduction in facial lesions with preventive HT-001.","HT-001 uses 505(b)(2) pathway; IND open; NDA submission targeted for 2030.","No FDA-approved therapy exists for EGFRI-induced cutaneous toxicities; HT-001 seeks first-in-market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158363,"accession_number":"0001213900-25-055834","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics regains Nasdaq minimum bid price compliance after 10-day closing above $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 18, 2025 confirming compliance with Listing Rule 5550(a)(2) after 10 consecutive business days at or above $1.00.","Compliance period ran from June 4 through June 17, 2025; Nasdaq matter is now closed.","CEO Robb Knie stated the milestone reflects growing market confidence and positions for value creation in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158362,"accession_number":"0001213900-25-052295","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics updates pipeline timelines, reports cash runway and share count in corporate deck","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash on hand sufficient to fund all clinical and preclinical programs in development.","13.2 million shares outstanding as of June 6, 2025; no outstanding debt noted.","HT-001 Phase 2a open-label PK data expected Q1 2025; full dataset Q4 2025.","HT-KIT IND submission targeted Q1 2026; GLP tox & GMP API manufacturing initiated Q1 2025.","HT-ALZ pre-IND meeting submission planned for 2025; 505(b)(2) pathway pursued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158361,"accession_number":"0001213900-25-044894","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Hoth Therapeutics receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price of common stock below $1.00 for 30 consecutive business days ending May 12, 2025.","Company has 180 days, until November 10, 2025, to regain compliance with minimum bid price rule.","To cure, stock must close at or above $1.00 for at least 10 consecutive business days.","Company may consider a reverse stock split among available options to regain compliance.","Nasdaq notice has no immediate effect on trading; stock continues on Nasdaq Capital Market under HOTH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158360,"accession_number":"0001213900-25-038694","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Hoth subsidiary's PCT patent application for hair loss treatment fee-confirmed","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Merveille.ai received USPTO confirmation that PCT/US2025/022598 fees were paid in full.","Application covers treatment and prevention of hair loss, with priority date April 5, 2024.","Filing supports Merveille.ai's intellectual property strategy for therapeutic innovation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158359,"accession_number":"0001213900-25-031763","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics reports positive Phase 2a interim data for HT-001: 50% reduction in pruritus by Day 21","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean pruritus score dropped 50% from 1.6 to 0.8 by Day 21 in open-label portion of CLEER-001 Phase 2a trial.","Rapid symptom relief: mean score improved to 1.0 by Day 7; some patients achieved complete resolution within 21 days.","HT-001 was well tolerated with no treatment-related serious adverse events reported.","Director Graig Springer resigned effective April 15, 2025; Wayne Linsley appointed as chair of nominating and governance committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176739,"accession_number":"0001013762-25-002271","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01","4.02","9.01"],"status":"ready","headline":"Hoth restates 2023, 2024 financials for prepaid R&D errors; initiates HT-KIT toxicity study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restatement: prepaid expenses understated by $722,765 at Dec 31, 2023; R&D expenses understated by $260,732 for FY2023.","Quarterly restatements for 2023-2024: prepaid assets understated by $442k-$983k; R&D expenses understated by $52k-$280k.","Enters Project Order with OnTargetx for 4-week IV toxicity study of HT-KIT (mast cell cancer) at cost of $354,219.","Restatement impacts operating cash flows but total cash unchanged; 2024 10-K to include restated periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176738,"accession_number":"0001213900-25-011325","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics increases ATM offering capacity by $5M to $7.7M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased maximum aggregate offering under ATM facility with H.C. Wainwright by $5M.","Approximately $2.7M in shares already sold under the facility prior to this increase.","Combined total potential offering now up to $7.7M.","Offering dilutes existing shareholders; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176737,"accession_number":"0001213900-25-006526","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics regains Nasdaq compliance on minimum bid price requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 23, 2025 that stock closed at or above $1.00 for 10 consecutive business days (Jan 7-22, 2025).","Compliance with Nasdaq Listing Rule 5550(a)(2) achieved; delisting matter closed.","CEO Robb Knie said milestone reinforces commitment to long-term shareholder value.","Company continues advancing its biopharmaceutical pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193558,"accession_number":"0001213900-24-104567","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics releases December 2024 corporate presentation highlighting pipeline and milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HT-001 Phase 2a for EGFR inhibitor skin toxicity: all sites active, enrolling open-label and double-blind; interim PK data expected Q1 2025.","HT-KIT: pre-IND meeting with FDA successful; IND-enabling tox studies ongoing; IND submission target Q4 2025.","HT-ALZ: US patent awarded Q3 2024; preclinical studies completed at WashU; pre-IND meeting planned for 2025.","BioLexa Phase 1b data readout completed in 2023; proof-of-concept results shown; non-corticosteroid treatment for atopic dermatitis.","7.7M shares outstanding as of Nov 29, 2024; cash on hand sufficient to fund current clinical and preclinical programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193557,"accession_number":"0001213900-24-100368","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics board approves up to $1M in Bitcoin as treasury reserve asset","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized purchase of up to $1 million in Bitcoin as a treasury reserve asset.","CEO Robb Knie cites Bitcoin's inflation-resistant characteristics and growing institutional acceptance.","Company supplements risk factors with Bitcoin price volatility warning in its 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193556,"accession_number":"0001213900-24-096007","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Hoth Therapeutics enters into $2.7M ATM offering with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM facility to sell up to $2.7M of common stock on Nasdaq through H.C. Wainwright as sales manager.","Wainwright receives 3.0% commission on gross proceeds; company reimburses certain expenses.","Company not obligated to sell any shares; may suspend sales at any time.","Agreement terminates upon sale of full $2.7M or by termination by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193555,"accession_number":"0001213900-24-093514","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Hoth Therapeutics receives Nasdaq deficiency notice for minimum bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified HOTH on Oct 30, 2024 that common stock failed minimum $1.00 bid price for 30 consecutive business days.","Common stock continues trading on Nasdaq Capital Market under HOTH; no immediate effect on listing.","Company has 180 days, until April 28, 2025, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant by April 28, 2025, an additional 180-day period may be granted if other listing requirements are met.","Company may consider implementing a reverse stock split to cure the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209866,"accession_number":"0001213900-24-066130","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Hoth Therapeutics shareholders re-elect board, ratify auditor, approve equity plan increase","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five incumbent directors re-elected; vote totals ranged from 637,415 to 700,399 for each.","Ratification of WithumSmith+Brown as auditor passed with 1,763,403 votes for (79.1% of votes cast).","Amendment to 2022 Omnibus Equity Plan approved to increase reserved shares from 591,317 to 1,091,317.","Quorum of 2,230,078 shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228064,"accession_number":"0001213900-24-053359","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Hoth Therapeutics board amends bylaws to clarify shareholder voting entitlement","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Board approved Amendment No. 2 to Amended and Restated Bylaws on June 14, 2024.","Amendment restates Article II, Section 2.7(b) regarding shareholders entitled to vote at meetings.","Effective immediately; no impact on financials or operations disclosed.","Exhibit 3.1 filed but not appended; details limited to procedural clarification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246821,"accession_number":"0001213900-24-026868","cik":1711786,"company_name":"Hoth Therapeutics, Inc.","ticker":"HOTH","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Hoth Therapeutics raises $4.2M via warrant exercise inducement, issues new warrants for 3.75M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.2M from immediate cash exercise of 2.5M existing warrants at reduced exercise price of $1.6775 (down from $5.00).","Company issues new unregistered warrants to purchase up to 3.75M shares at $1.50, exercisable immediately until July 3, 2028.","Offering expected to close on or about April 1, 2024; H.C. Wainwright acting as exclusive placement agent.","Net proceeds used for general working capital purposes.","Company agreed to file resale registration statement for shares underlying new warrants within 30 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13548108.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}